← Back to Clinical Trials
Recruiting NCT07758712

NCT07758712 Effectiveness of a Horse Riding Simulator in Adolescents With Idiopathic Scoliosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07758712
Status Recruiting
Phase
Sponsor Bezmialem Vakif University
Condition Scoliosis Idiopathic Adolescent
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-08-05
Primary Completion 2027-01-10

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 19 Years
Study Type INTERVENTIONAL
Interventions
Horse Riding SimulatorCore Stabilization Exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-08-05 with a primary completion date of 2027-01-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Adolescent idiopathic scoliosis (AIS) is a three-dimensional spinal deformity associated with impaired respiratory muscle strength, balance, postural control, body image, and health-related quality of life. Core stabilization exercises are widely used in the conservative management of AIS. Horse riding simulator training reproduces the multidirectional rhythmic movements of horseback riding while eliminating the potential risks associated with conventional hippotherapy and may provide additional benefits for postural control and trunk muscle activation. The aim of this randomized controlled trial is to investigate the effects of adding horse riding simulator training to a core stabilization exercise program on respiratory muscle strength, balance, health-related quality of life, and perceived cosmetic deformity in adolescents with idiopathic scoliosis. Participants will be randomly assigned to either an experimental group receiving horse riding simulator training combined with core stabilization exercises or a control group receiving core stabilization exercises alone. Outcomes will be assessed before and after the 12-week intervention.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of adolescent idiopathic scoliosis * Age between 10 and 19 years * Cobb angle between 10° and 40°, measured on standing spinal radiographs * Willingness of the participant and, when applicable, the parent or legal guardian to participate in the study Exclusion Criteria: * Scoliosis of a non-idiopathic etiology * History of surgery within the previous 3 months * Presence of an orthopedic, neurological, or systemic condition that may prevent participation in the exercise program * Cognitive, communication, or behavioral disorders that may interfere with understanding instructions, answering questions, or performing the exercises * Participation in regular exercise on 3 or more days per week

Contact & Investigator

Central Contact

Sefa Yıldırım

✉ syildirim@bezmialem.edu.tr

📞 +905385984870

Frequently Asked Questions

Who can join the NCT07758712 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 19 Years, studying Scoliosis Idiopathic Adolescent. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07758712 currently recruiting?

Yes, NCT07758712 is actively recruiting participants. Contact the research team at syildirim@bezmialem.edu.tr for enrollment information.

Where is the NCT07758712 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07758712 clinical trial?

NCT07758712 is sponsored by Bezmialem Vakif University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology